6,041 Shares in argenex SE $ARGX Acquired by Virtu Financial LLC

Virtu Financial LLC bought a new stake in argenex SE (NASDAQ:ARGX) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 6,041 shares of the company’s stock, valued at approximately $5,080,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. M&T Bank Corp boosted its holdings in shares of argenex by 20,977.7% in the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock valued at $654,772,000 after purchasing an additional 774,916 shares during the last quarter. Sands Capital Management LLC increased its holdings in shares of argenex by 2,046.6% during the 4th quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock worth $300,110,000 after buying an additional 340,245 shares during the last quarter. Invesco Ltd. increased its holdings in shares of argenex by 390.4% during the 4th quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock worth $350,178,000 after buying an additional 331,489 shares during the last quarter. Wellington Management Group LLP raised its position in shares of argenex by 80.1% in the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after buying an additional 324,653 shares during the period. Finally, Two Sigma Investments LP raised its position in shares of argenex by 570.3% in the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after buying an additional 250,278 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on ARGX. Wedbush reissued an “outperform” rating and set a $1,000.00 price target on shares of argenex in a research report on Thursday, June 11th. Wall Street Zen downgraded argenex from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Deutsche Bank Aktiengesellschaft raised argenex from a “hold” rating to a “buy” rating in a research note on Tuesday, March 10th. Robert W. Baird boosted their target price on argenex from $858.00 to $867.00 and gave the stock a “neutral” rating in a report on Friday, February 27th. Finally, Citizens Jmp increased their target price on shares of argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a research report on Friday, February 27th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,019.50.

argenex Price Performance

NASDAQ:ARGX opened at $877.72 on Friday. The business’s 50-day moving average is $822.61 and its two-hundred day moving average is $810.57. argenex SE has a 12 month low of $510.05 and a 12 month high of $934.62. The firm has a market capitalization of $54.59 billion, a PE ratio of 39.08, a price-to-earnings-growth ratio of 1.36 and a beta of 0.47.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%.The company had revenue of $1.31 billion for the quarter. Equities analysts anticipate that argenex SE will post 26.19 EPS for the current year.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.